Zenas BioPharma, Inc.: Xencor Inc amends Schedule 13G stake filing
Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 5 November 2026, by SEC EDGAR SCHEDULE 13G
25Impact 25 of 100, routine
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Xencor Inc. filed an amended Schedule 13G with the SEC disclosing a change to its passive stake in Zenas BioPharma, Inc., under accession number 0001326732-26-000066. The filing signals a shift in Xencor's ownership position in the clinical-stage autoimmune and inflammatory biotech. Investors should watch for further 13G amendments or 13D filings to gauge whether Xencor's interest remains passive or becomes activist.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Zenas BioPharma, Inc., Xencor Inc